A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog, Martin T. Lowy, Richard A. Grove, Richard S.E. Keefe, Joseph P. Horrigan, M. Patricia Ball, Alan Breier, Robert W. Buchanan, Cameron S. Carter, John G. Csernansky, Donald C. Goff, Michael F. Green, Joshua T. Kantrowitz, Matcheri S. Keshavan, Marc Laurelle, Jeffrey A. Lieberman, Stephen R. Marder, Paul Maruff, Robert P. McMahon, Larry J. SeidmanMargaret A. Peykamian

Research output: Contribution to journalArticle

24 Scopus citations

Fingerprint Dive into the research topics of 'A Phase II study of a histamine H<sub>3</sub> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences